Good 5-Year Durability of Transapical Beating Heart Off-Pump Mitral Valve Repair With Neochordae

Thursday, August 30, 2018

Submitted by

Source

Source Name: The Annals of Thoracic Surgery

Source URL: https://doi.org/10.1016/j.athoracsur.2018.01.092

Author(s)

Philipp Kiefer, Sabine Meier, Thilo Noack, Michael Andrew Borger, Joerg Ender, Alexandro Hoyer, Friedrich Wilhelm Mohr, Joerg Seeburger

Kiefer and colleagues report the outcomes of six patients who underwent transapical mitral valve repair for severe mitral regurgitation. Treatment was offered as part of the safety and feasibility trial for the NeoChord DS1000 system at the authors’ institution. One patient underwent intraoperative conversion to an open repair, two patients underwent reoperation for recurrent mitral regurgitation, and the remaining three patients had no cardiac symptoms throughout the five-year follow-up period.

Comments

Submitted by Aristotle Protopapas on Fri, 2018-08-31 04:35

Small case series that has to be read in the wider context of https://www.ctsnet.org/jans/percutaneous-repair-or-medical-treatment-secondary-mitral-regurgitation#comment-2326

Submitted by T. Sloane Guy on Fri, 2018-08-31 22:31

As exciting as this new technology is, the title “Good 5-Year Durability...” does not accurately reflect the results with a 50% failure rate (one conversion and two reoperations). It’s very misleading. When considering the idea that this would be used in otherwise reasonable surgical candidates this report should yield some concern and we certainly need much more data before we consider such therapies in all but the highest risk patients.